Surgical Sutures Market 2019 – Summary Of Recent Innovations 2025

The global surgical suture market size is expected to reach at USD 5.9 billion by 2025, according to a new report by Grand View Research, Inc. It is anticipated to expand at a CAGR of 6.5% over the forecast period. The increasing cases of complicated surgeries and awareness regarding patient safety during surgeries are expected to drive the market in the next few years.

Aging baby boomers and introduction of various sutures by the market players are other high impact rendering market drivers. For instance, in November 2015, the U.S. Food and Drug Administration (FDA) approved RESORBA suture range developed by Advanced Medical Solutions Group plc.

Furthermore, advantages associated with multivalent sutures over staples and adhesives in complicated surgeries are likely to propel the market growth during the forecast period. Staples cause more pain and are less precise in complicated wound closure, hence sutures are preferred over staples. This factor is anticipated to bode well for the growth of the market for surgical sutures over the forecast period.

Increasing number of surgical procedures due to the presence of a large geriatric population, government support in various countries, and favorable reimbursement scenario are likely to further drive the market in the forthcoming years.

The type segment comprises absorbable and non-absorbable sutures. Absorbable suture provides temporary support to wound till it heals, can withstand normal stress, and there is no need to remove it post-surgery as it gets absorbed in the body after a certain period. This factor is anticipated to drive the demand for this type in near future.

 To request a sample copy or view summary of this report, click the link below: 

https://www.grandviewresearch.com/industry-analysis/surgical-sutures-market

Further key findings from the study suggest:

• Absorbable suture accounted for the largest market share in 2017 and is expected to maintain its share in the coming years
• Multivalent filament accounted for the maximum market share in 2017 due to its high strength, pliability, and more flexibility than monovalent filament
• Cardiovascular surgery segment accounted for the largest share of the market by application in 2017, attributed to adoption of minimally invasive surgeries and rising number of cardiovascular surgeries performed around the world due to high incidence of cardiovascular diseases and development
• North America accounted for the largest share of the surgical sutures market in 2017 and is expected to maintain its dominance in the coming years due to the presence of major market players
• Some of the major market players are Ethicon Inc.; Medtronic; Integra LifeSciences; Péters Surgical; Internacional Farmacéutica; Sutures India Pvt. Ltd.; B. Braun Melsungen AG; and Smith & Nephew.

Microfluidics Prototype Market 2019 | Business Overview, Investment Analysis, Insights, Outlook And Forecast 2025

The global microfluidics prototype market size is expected to reach USD 1.8 billion by 2025, according to a new report by Grand View Research, Inc. It is projected to register a CAGR of 20.54% over the forecast period.Introduction of advanced technologies, increasing demand for low volume sample analysis, and emergence of 3D printing technology are among the key factors likely to drive the market during the forecast period.

The microfluidics prototype market is anticipated to witness high growth in the forthcoming years due to increasing investment by key market players to expedite technological innovations in the developing industry. In July 2018, TechX Pioneer Program of the Oil and Gas Technology Center, awarded RAB Microfluidics with a 12-month fellowship platform including business development training, mentorship from business consultants, and funding aid. The grant was made for the development of a miniature lab-on-chip technology for rotating equipment offering predictive failure analysis and real-time condition monitoring.

The development of microfluidics devices involves a high operational cost due to functions, such as microfabrication. Moreover, most of the prototyping methods for microfluidics devices are not compatible with batch process. The scale-up of this method is a costly and complicated affair. This has led to an emphasis on the development of cheaper systems. For instance, in March 2018, researchers from the National University of Singapore (NUS) developed a microfluidic chip that can detect nano-bioparticles without the use of fluorescent labels providing disease diagnosis at a low cost.

Rising research and development activities are anticipated to bode well for market growth in Asia Pacific. For instance, in India, the Microfluidics and Biological Physics Group of Indian Institute of Technology Bombay uses microfluidics technology to build point-of-care diagnostic platforms. The team uses conventional microfluidic devices and different alternate substrates to design and develop affordable lab-on-chip platforms.

The global market for microfluidics prototype is startup-driven and is highly supported by government and private institutions. For instance, in October 2017, the National Institute of Health, USA, awarded Neofluidics with a Phase 1 Small Business Innovation Research (SBIR) grant of USD 175,000. The grant was allotted to develop a microfluidic device for drug screening and disease modeling studies using zebrafish embryos.

 To request a sample copy or view summary of this report, click the link below: 

https://www.grandviewresearch.com/industry-analysis/microfluidics-prototype-market

Further key findings from the report suggest:

• Introduction of advanced technologies, increasing demand for low volume sample analysis, and emergence of 3D printing technologyare expected to propel the market at a CAGR of 20.54% from 2018 to 2025
• North America held the largest market share in 2017 and is expected to maintain its dominance during the forecast period due to the presence of more than 170 service providers, abundant funding opportunities, and R&D investments
• Asia Pacific region is anticipated to spearhead the market in terms of growth rate over the forecast period. Presence of university research groups and spinoffs contribute significantly to the growth.
• Key contributors in microfluidics prototype market are microLIQUID; thinXXS Microtechnology; Potomac; uFluidix; Alvéole; Micronics, Inc.; ALine, Inc.; and research groups from various universities.
• 
  

Rosacea Treatment Market Opportunities, Competitive Benchmarking, Company Market Shares and Market Forecasts By 2019- 2025

The global rosacea treatment market size is expected to reach USD 2.6 billion by 2025, according to a new report by Grand View Research, Inc. It is anticipated to register a CAGR of 6.8% over the forecast period. Several factors such as an advanced formulations and high prevalence of the disease are forecasted to fuel the market growth.

Rosacea affects more than 400 million people worldwide and the global incidence among adults is estimated at 5%. Less than 1.5 million patients seek treatment, making it a highly underdiagnosed condition. This disease has a higher incidence in women than men, with several studies claiming a possible association between rosacea and menopause. In the absence of an absolute cure, treatment options are largely focused on management of the disease.

The market for rosacea treatment is majorly genericized due to multiple patent expiries, leading to a highly fragmented therapeutic landscape. Rosacea is an underdiagnosed condition and is frequently misdiagnosed as acne. Off-label use of therapeutics pose an intensely competitive space for rosacea-specific treatments.

Topical therapies remain the mainstay for treatment. Topical products captured more than 60% market share in 2017. Although topical items are expected to maintain their lead over oral medicines through the forecast period, the market is witnessing a paradigm shift supported by the increasing inclination towards combination products.

Therapeutic options available for rosacea treatment are antibiotics, alpha agonists, retinoids, immunosuppressants, corticosteroids, antihypertensive agents, and others. Antibiotics are prescribed for the first-line treatment, making them the dominant drug class in 2017-a trend expected to continue through 2025.

The rosacea treatment market growth is supported by strong commercial sales from key products such as Rhofade, Mirvaso, Oracea, MetroGel, Noritate, and Finacea. Although increased penetration of generic drugs is a constraining factor, the impending launch of several promising pipeline products indicate an optimistic future for the global market.

 To request a sample copy or view summary of this report, click the link below: 

https://www.grandviewresearch.com/industry-analysis/rosacea-treatment-market

Further key findings from the report suggest:

• The topical drugs segment held over 65% market share in 2017. These drugs are generally prescribed as first-line treatments and are preferred over other options in terms of convenience and results
• Alpha agonists is anticipated to be the fastest growing drug class, with a CAGR of over 8% during the forecast period
• Geographically, North America and Europe are the leading regions as the disease tends to affect people with fair/light skin. Asia Pacific is anticipated to witness the fastest growth owing to improved economic and healthcare scenario
• Key players operating in the rosacea treatment market include Bayer Schering AG; Bausch Health Companies Inc.; Foamix Pharmaceuticals; Nestlé S.A.; and Allergan Plc.

Nasal Drug Delivery Technology Market 2019 Size, Industry Status & Growth Opportunity

The global nasal drug delivery systems market size is expected to reach USD 67.99 billion by 2025 expanding at 6.5% CAGR, according to a new report by Grand View Research, Inc. Rising awareness about nasal products is one of the major factors driving the market. Growing geriatric population is also expected to have positive impact on the market. According to the United Nations Department of Economic and Social Affairs, the global geriatric population (60 years and above), was around 962 million in 2017. The number is expected to grow, particularly in Latin America with 71% rise in population aged 60 and over, followed by Asia (66%), Africa (64%), North America (41%), and Europe (23%).

Moreover, ongoing product development and their expected commercialization will propel market growth over the forecast period. For instance, In April 2018, Dr. Reddy’s Laboratories, along with its subsidiary Promius Pharma, LLC, announced filing of their New Drug Application (NDA) for DFN-02, for the treatment of migraine. Increasing adoption of self-administration practices and focus on other alternative routes of drug delivery, such as nasal drug delivery, also offer growth opportunities for the market. Some of the key companies in the industry are AstraZeneca PLC; OptiNose, Inc.; Pfizer, Inc.; Becton, Dickinson and Company; Promius Pharma LLC; B.F. Ascher & Company, Inc.; and Cadila Pharmaceuticals Ltd.

 To request a sample copy or view summary of this report, click the link below: 

https://www.grandviewresearch.com/industry-analysis/nasal-drug-delivery-technology-system-market

Further key findings from the study suggest:

• Nasal sprays led the dosage type segment in 2017 due to increased prevalence of asthma and other infectious diseases
• On the other hand, nasal drops segment witnessed the fastest growth in 2017 owing to availability of cost-effective products with better efficacy
• Non-pressurized containers segment led the market in 2017 due to continous development in nasal powders and gel products
• Asthma was the dominant therapeutic application segment in 2017 and is estimated to be the fastest-growing segment with a CAGR of 7.0% during the forecast years due to increasing disease prevalence
• Geographically, North America held the largest share in 2017. Asia Pacific is estimated to witness the fastest CAGR of 7.5% due to presence of key companies, such as Cipla Inc.
• Some of the leading companies in the global nasal drug delivery technology market are GlaxoSmithKline PLC; AstraZeneca PLC; Pfizer, Inc.; OptiNose, Inc.; Becton, Dickinson and Company; Promius Pharma, LLC; Cadila Pharmaceuticals Ltd.; B.F. Ascher & Company, Inc.; PendoPharm, Inc.; Douglas Pharmaceuticals Ltd.; ENT Technologies Pty. Ltd.; and NAVEH Pharma Ltd.

Hand-held Surgical Instruments Market 2019-2025 Insight Dynamic Key Players, Applications, and Regions

The global hand-held surgical instruments market size is expected to reach USD 6.51 billion by 2025 at a 7.1% CAGR during the forecast period, according to a new report by Grand View Research, Inc. The market is anticipated to be driven by rise in number of surgical procedures being performed and increase in prevalence of chronic diseases. In addition, rise in number of road and other accidents globally is contributing to high demand for these surgical instruments.

According to data revealed by the Center for Disease Control and Prevention (CDC) in 2017, 15% of the U.S. population suffers from chronic kidney disease. Hence, with rising prevalence of chronic diseases, need for surgical treatment has been increasing. This is, in turn, accelerating demand for handheld surgical instruments. As per WHO, around 10 million people are injured or disabled due to road accidents every year, which has also resulted in growing number of wound surgeries. This is expected to positively impact market growth in the long run.

In addition, as per Plastic Surgery Statistics Report released by the American Society of Plastic Surgeons, in U.S., around 17.5 million cosmetic surgeries and minimally invasive procedures were performed in 2017. This showcases that the number of surgeries being performed is expected to rise in future.

 To request a sample copy or view summary of this report, click the link below: 

https://www.grandviewresearch.com/industry-analysis/hand-held-surgical-instruments-market

Further key findings from the study suggest:

• By product, the others segment dominated the market in 2017 owing to high adoption of various types of surgical tools such as clamps, cannulas, closure devices, bone rasps, needle holders, dissectors, suction tubes, and other cutting instruments
• Rise in general surgeries, wound injuries, and urologic surgeries, such as prostate cancer surgery and urinary obstruction surgery, has led to high revenue generation of the others segment by application
• Plastic and reconstructive surgery is expected to witness the fastest growth over the forecast period due to rise in number of cosmetic surgical procedures such as liposuction, breast augmentation, and abdominoplasty
• On the basis of end use, the hospitals segment is fueled by presence of well-equipped operating rooms
• Clinics held a significant revenue share in 2017 owing to rise in number of dental and other specialized clinics throughout the world, resulting in increased demand for handheld surgical tools
• North America dominated the market in 2017 due to presence of well-developed healthcare infrastructure and leading market players in the region; Asia Pacific is projected to showcase the highest growth during the forecast period owing to rising prevalence of chronic diseases, burn cases, and high child birth rate
• Some of the key companies are B. Braun Melsungen AG, Integra LifeSciences Corporation, Smith & Nephew, Medtronic, Zimmer Biomet Holdings, Becton, Dickinson and Company, and Johnson & Johnson.

Brachytherapy Market 2019 – 2025 Industry Dynamics, Segmentation, Regional Outlook and Competition Analysis

The global brachytherapy market size is expected to reach USD 452.3 million by 2025, according to a new report by Grand View Research, Inc. It is projected to register a CAGR of 4.8% over the forecast period. Technological advancements and R&D investments by key market players are some of the major growth drivers. In August 2017, Salutaris Medical Devices launched the trial of brachytherapy treatment for neovascular age-related macular degeneration. The trial is to study surgeons’ ease in using SalutarisMD system (SMD-DA system) along with the anti-VEGF treatment regimen and the safety of the same.

According to the International Agency for Research on Cancer, in 2015, more than 15 million people suffered from cancer while 8.8 million deaths were caused by the disease worldwide. This number is expected to rise to 24 million by 2035. It is also estimated that 23.6 million new cancer cases will be diagnosed by 2030.

According to the American Brachytherapy Society, safety, and efficacy of brachytherapy treatment over other cancer treatments, such as chemotherapy and surgery, is expected to boost the market. In addition, favorable reimbursement guidelines are expected to contribute to the rising adoption of brachytherapy.

The Center for Medicare and Medicaid (CMS) implemented new High-Dose Rate (HDR) treatment delivery codes in 2016. The final rates for 2017 included an increase of approximately 5% to 6% in payments. Increasing usage of these technologies and the presence of favorable reimbursement policies in developing countries are expected to further fuel growth of the brachytherapy market.

 To request a sample copy or view summary of this report, click the link below: 

https://www.grandviewresearch.com/industry-analysis/brachytherapy-devices-market

Further key findings from the study suggest:

• In 2017, HDR brachytherapy held the largest market share in terms of revenue. The segment is also expected to witness the fastest CAGR over the forecast period due to the growing incidence of breast cancer, unhealthy lifestyle, rising R&D investments, and the introduction of technologically improved treatment solutions
• Application segment is further divided into prostate cancer, breast cancer, gynecological cancer, and other types of cancer. Breast cancer is expected to witness the fastest CAGR over the forecast period
• North America held the dominant market in terms of revenue in 2017. On the other hand, Asia Pacific is expected to witness the fastest CAGR over the forecast period
• Eckert & Ziegler BEBIG; iCAD, Inc.; IsoRay Medical, Inc.; Elekta AB; C.R. Bard, Inc.; CIVCO Medical Solutions; etc. are some of the key players in the brachytherapy market.

Diabetic Foot Ulcer Treatment Market Size Worth USD 6.82 Billion By 2025 – Challenges, Prospects, Business Profiles And Competitive Landscape

The global diabetic foot ulcer treatment market size is expected to reach a value of USD 6.82 billion by 2025, according to a new report by Grand View Research, Inc., progressing at a CAGR of 8.2% during the forecast period. Rising prevalence of diabetes, increasing healthcare expenses, and rapidly growing geriatric population worldwide are some of the major factors driving the diabetic foot ulcer treatment market.

Diabetic foot ulcers are one of the most common foot injuries that is caused due to diabetes mellitus. Management of diabetic foot ulcers aims at fast healing and wound closure, by adopting a multidisciplinary therapeutic approach so as to avoid amputation. Among different types of treatment options available, biologics held the largest share in the diabetic foot ulcer treatment market in 2017. This can be attributed to strong revenue generated by growth factors that are prescribed worldwide for their ability to promote generation of new cells and achieve wound closure. Therapy devices and wound care dressings also offer significant commercial opportunity due to their cost-effectiveness, ease of availability, and wide use in combination with other treatments at every level of wound care management.

Among different ulcer types, neuro-ischemic ulcers led the market in 2017 with more than 50.0% market share due to higher patient population suffering from the ulcer type globally. North America represented the largest share in the global market in 2017 owing to rising prevalence of diabetes, growing geriatric cohort, increased investment in R&D of novel therapies, and developed healthcare facilities.

 To request a sample copy or view summary of this report, click the link below: 

https://www.grandviewresearch.com/industry-analysis/diabetic-foot-ulcer-dfu-treatment-market

Further Key Findings From the Study Suggest:

• The biologics segment commanded the largest share in 2017 and is projected to retain its position through the forecast period, due to increased adoption and potential approvals of growth factors
• North America dominated the DFU treatment market in 2017 due to well-established favorable healthcare reimbursements and infrastructure
• Asia Pacific is expected to witness the fastest growth owing to expanding diabetes patient population driven by increasing healthcare expenses and growing geriatric cohort
• The neuro-ischemic ulcers segment accounted for the leading share in 2017. It is likely to experience the fastest growth during the forecast period
• The foam and alginate dressings, skin grafts, and negative pressure wound therapy segments are anticipated to exhibit significant CAGR over the forecast period
• Some of the key players in this space are ConvaTec, Inc.; Acelity L.P. Inc.; 3M Healthcare; Coloplast A/S; Smith & Nephew Plc.; B. Braun Melsungen AG; Medline Industries, Inc.; Medtronic Plc.; Organogenesis, Inc.; Molnlycke Health Care AB; and BSN Medical GMBH.